Ruxolitinib

Ruxolitinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Myelofibrosis、Primary Myelofibrosis (PMF)、Post-polycythemia Vera Myelofibrosis (PPV-MF)、Post-essential Thrombocythemia Myelofibrosis (PET-MF)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Ruxolitinib 研究

• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  I 期招募中美国NCT06034002

• A Trial of Selinexor, Ruxolitinib and Methylprednisolone

  I 期招募中美国NCT06225310

• High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

  II 期招募中美国NCT06345495

• Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

  II 期招募中美国NCT04370301

• A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

  I 期招募中美国澳大利亚NCT07849231

• Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

  II 期招募中RussiaNCT07238712

• Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

  I 期招募中美国NCT06008808

• Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

  早期 I 期招募中美国NCT04744116

• Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

  II 期招募中中国NCT07509749

• Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

  不适用招募中意大利NCT06516406

• Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

  IV 期招募中中国NCT07101588

• Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

  I 期招募中美国NCT07025538

• Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

  I 期招募中美国NCT07424222

• Amping up With PemJAK

  II 期招募中美国NCT07283822

• Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

  II 期招募中中国香港NCT06770842

• Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)

  II 期招募中美国NCT06160791

• ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

  不适用招募中中国NCT07454226

• Ruxolitinib Treatment in Inclusion Body Myositis

  II 期招募中法国NCT06536166

• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

  II 期 / III 期招募中RussiaNCT07366801

• Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

  II 期招募中中国NCT07572669

• Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD

  不适用招募中中国NCT07184853

• A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

  III 期招募中美国NCT06615050

• A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  III 期招募中美国Argentina澳大利亚奥地利NCT07623161

• Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

  II 期招募中美国NCT06128070

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。